VC Deals
CeQur SA, a Swiss developer of insulin infusion solutions for people with diabetes, has raised $100 million in Series C funding. Woodford Investment Management and Arthurian Life Sciences co-led the round, and were joined by return backers Endeavour Vision, Schroder & Co. Banque SA and VI Partners
Intellia Therapeutics, a Cambridge, Mass.-based gene-editing company focused on the development of medicines using CRISPR/Cas9 technology, has raised $70 million in Series B funding. OrbiMed led the round, and was joined by Fidelity, Janus Capital Management, Foresite Capital, Sectoral Asset Management, EcoR1 Capital and return backers Atlas Venture and Novartis
Ivenix Inc., an Amesbury, Mass.-based developer of an infusion management system, has raised $42 million in new equity funding. WuXi Healthcare Ventures led the round, and was joined by Cardinal Partners, CICA, Inc., Easterly Ventures, Fidelity Biosciences, SCP Vitalife Partners and Stichting Lichfield. Leerink Partners served as placement agent
Medfusion Inc., a Cary, N.C.-based patient engagement platform, has raised $3 million in VC funding from Bull City Venture Partners and Hatteras Venture Partners
ADC Therapeutics, a Switzerland-based developer of antibody drug conjugates targeting cancer, has raised $80 million in equity funding from backers like Auven Therapeutics and AstraZeneca
DecisionSim, a 5.5-year-old, Chadds Ford, Pa.-based maker of health care simulation-based learnings tools, has raised $1.85 million in Series A funding led by Philadelphia-based Rittenhouse Ventures, with participation from Ben Franklin Technology Partners
Exosome Diagnostics, a seven-year-old, New York-based company that develops and commercializes blood-based cancer molecular diagnostics for disease monitoring, has raise $17.6 million in Series B-1 funding that brings the entire round to $44.7 million. Participants in this newest financing included Forbion Capital Partners, NGN Capital, Arcus Ventures, Tiger Global Management, and CD Ventures
PE Deals
Trimb Healthcare AB, a Swedish portfolio company ofAvista Capital Partners, has agreed to acquire YouMedical Group AB, a Dutch provider of OTC healthcare products that generates around 16 million in annual revenue. No financial terms were disclose
Medivo Inc., a New York-based provider of lab data analytics, has sold its lab testing authorization services unit to PWNHealth LLC, a new company formed byEDG Partners. No financial terms were disclosed. Medivo shareholders include Merck Global Health Innovation, MentorTech Ventures and Safeguard Scientifics
MidOcean Partners has made a “significant investment” in Image Skincare, a Palm Beach, Fla.-based maker of branded products for the professional skincare market
Simcro Ltd., a New Zealand-based animal health company owned by The Riverside Company, has acquired the assets of ISL Animal Health and NJ Philips Pty Ltd. No financial terms were disclosed
Clinical Pharmacy Services, a Gary, Tenn.-based operator of radiopharmacies and mobile PET/CT imaging units, has secured an undisclosed amount of equity funding from Webster Capital
Leonard Green & Partners has acquired RestorixHealth, a Tarrytown, N.Y.-based provider of wound care management solutions to hospitals, from Sverica International. No financial terms were disclosed
Marlin Equity Partners has acquired AdvancedMD, a South Jordan, Utah-based provider of software to the independent physician practice market, from Automatic Data Processing (Nasdaq: ADP). No financial terms were disclosed
Thoma Bravo has agreed to acquire a majority stake inMedeAnalytics Inc., an Emeryville, Calif.-based provider of cloud-based financial performance analytics for the healthcare industry. Existing investors Bain Capital Ventures and Emergence Capital Partners will remain minority shareholders. No financial terms were disclosed
SurgCenter Development, a Pismo Beach, Calif.-based operator of ambulatory surgery centers, has hired Greenhill & Co. to handle a sale process that has attracted private equity interest, according to LBO Wire. The company is expected to generate more than $142 million in EBITDA during its current fiscal year, which means a buyer may pay upwards of $1.5 billion
IPO Deals
Cortendo, a Swedish drug company focused on rare endocrine disorders, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol SBBP, with BofA Merrill Lynch and Stifel serving as lead underwriters. The pre-revenue company is currently listed on the Norwegian Over-The-Counter System, and is backed by such shareholders as TVM Capital (12.5% pre-IPO stake), HealthCap (11.8%), RA Capital (10.8%) and New Enterprise Associates (8.5%)
CytomX Therapeutics, a South San Francisco-based developer of cancer therapeutics, has filed for a $100 million IPO. It plans to trade on the Nasdaq under ticker symbol CTMX, with BofA Merrill Lynch, Jefferies and Cowen & Co. serving as lead underwriters. The company reports around a $12 million net loss on nearly $4 million in revenue for the first half of 2015. It has raised over $130 million in VC funding, including a $70 million Series D round this past June. Shareholders include Third Rock Ventures (30.8% pre-IPO stake), Canaan Partners (17.4%), Fidelity (8.7%), Roche (6.8%), Pfizer (5.7%), Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors, Tekla Life Sciences Investors, Venrock and Wellington Management Co
PharMEDium Healthcare Holdings, a Lake Forrest, Ill.-based provider of outsourced compounded sterile preparations, has filed for a $100 million IPO. It plans to trade on the NYSE under ticker symbol PMHC, with Credit Suisse, J.P. Morgan and Morgan Stanley serving as lead underwriters. The company reports $9.3 million of net income on around $209.5 million of revenue for the first half of 2014, compared to less than $1 million of net income on $153 million in revenue for the year-earlier period. Clayton Dubilier & Rice acquired PharMEDium in early 2014 for around $900 million
Sancilio Pharmaceuticals Co., a Riviera Beach, Fla.-based developer of drugs based on lipid drug delivery technology, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol SPCI, with UBS and Piper Jaffray serving as lead underwriters. The company reports a $260,000 net loss on around $13.5 million in revenue for the first half of 2015. Shareholders include Signet Healthcare Partners (12.2% pre-IPO stake) and Wellington Management (12.2%)
GC Aesthetics, an Ireland-based breast implant maker focused on non-U.S. markets, has withdrawn registration for a $75 million IPO. has filed for a $75 million IPO. The company had originally filed for the offering in June 2014, with BofA Merrill Lynch, Deutsche Bank and Cowen & Co. serving as underwriters. It later reported an $89 million net loss on $52.8 million in revenue for 2014. Shareholders include Montreux Equity Partners (48% stake), Oyster Capital Partners (8.7%) and OrbiMed Advisors (8.2%)
PointClickCare, a Canadian electronic medical records software company, has filed for a $100 million IPO. It plans to list on the Nasdaq under ticker symbol PCLK, with J.P. Morgan, Goldman Sachs and RBC Capital Markets serving as lead underwriters. The company reports $268,000 in net income on nearly $59 million of revenue for the first half of 2015, compared to a $5.3 million net loss on $48 million of revenue for the year-earlier period. Shareholders include JMI Equity (25.8% pre-IPO stake)
Other Deals
GTCR has completed its previously-announced sale ofCapella Healthcare Inc., a Franklin, Tenn.-based operator of community hospitals, to Medical Properties Trust Inc. (NYSE: MPW) for $900 million in cash
HeartWare International Inc. (Nasdaq: HTWR) has agreed to acquire Valtech Cardio Ltd. an Israel-based provider of surgical and transcatheter valve repair and replacement devices. The deal could be worth more than $860 million, including an upfront stock payment valued at around $360 million. Valtech investors include GlenRock Israel, NGN Capital, Partech International, Peregrine Ventures and RAD BioMed
InVentive Health, a Burlington, Mass.-based portfolio company of Thomas H. Lee Partners, has sold its Somerset, N.J.-based patient access solutions business (iPAS) to Xerox Inc. (NYSE: XRX) for an undisclosed amount
Allergan PLC (NYSE: AGN) has agreed to acquireAqueSys Inc., an Aliso Viejo, Calif.-based developer of gel stent technology for treating glaucoma. The deal includes a $300 million upfront payment and unspecified earn-outs. AqueSys had raised around $90 million in VC funding from firms like Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures, and SV Life Sciences
Cipla Ltd., an India-listed pharmaceutical company, has agreed to acquire U.S. generic drug companies InvaGen Pharmaceuticals Inc. (Hauppauge, N.Y.). and Exelan Pharmaceuticals Inc. (Lawrenceville, Ga.) for a total of $550 million
Amicus Therapeutics, a publicly traded biopharmaceutical company in Cranbury, N.J., is acquiring Scioderm, a three-year-old, Durham, N.C.-based company that develops topical products to treat chronic skin diseases. It’s paying about $229 million in cash and stock — and there’s up to $681 million more up for grabs, with clinical and regulatory milestones thrown into the mix. Scioderm had raised $37 million from Morgenthaler Ventures, Technology Partners, and Redmile Group
Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg
#healthtech #asia